Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome.

Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome.

Indicaton

Insomnia in ASD

Therapeutic indications

Type of product

Small molecule

Table

Phase

Marketed
Available in

EMA Markets

You may also be interested in

Small molecule therapeutic that aims to treat Alzheimer’s patients

Alzheimer’s disease

Discovery

nizubaglustat

Has the potential to treat multiple rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses, and Niemann-Pick disease type C (NPC).

Phase II started

Morphomer NLRP3-ASC

Neuroinflammation

Discovery